openPR Logo
Press release

Expected Growth in Blood Cancer Drugs Market From 2017-2025: Trend, Analysis By Manufacturers, Regions, Type And Application | Global Manufacturer are Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer Inc., Eli Lily & Co., AstraZeneca, AbbVie Inc., Ro

11-03-2018 09:40 AM CET | Health & Medicine

Press release from: Polaris Market Research & Consulting

Expected Growth in Blood Cancer Drugs Market From 2017-2025:

The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 according to a new research report. The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.

Request for a sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-free-sample

Some of the key players in the global market include:

Johnson & Johnson Inc.
Amgen Inc.
Bayer AG.
Pfizer, Inc.
AbbVie Inc.
Roche Holding AG.
Celgene Corporation
AstraZeneca
Novartis AG
GlaxoSmithKline PLC
Merck & Co., Inc.
Eli Lily & Co.

Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs.

The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.

Make an inquiry for purchasing this report @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/inquire-before-buying

On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.

Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North America’s blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.

Browse Complete Report Summary @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/

Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.

Contact us-

Mr. Neel
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Expected Growth in Blood Cancer Drugs Market From 2017-2025: Trend, Analysis By Manufacturers, Regions, Type And Application | Global Manufacturer are Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer Inc., Eli Lily & Co., AstraZeneca, AbbVie Inc., Ro here

News-ID: 1350138 • Views: 244

More Releases from Polaris Market Research & Consulting

What's driving the Blockchain Technology Market Trends? Microsoft Corporation, I …
The worldwide market size for blockchain technology is estimated to grow at a CAGR of 41.6% between 2018 and 2026 and is anticipated to reach USD 16.82 billion by 2026. According to a new study published by Polaris Market Research. Also termed as Distributed Ledger Technology (DLT), blockchain enables secure transaction over a distributed network. Since the transactions are taken place usually over the network, it is difficult to reverse
What's driving the Precision Farming Market Trends? Ag Leader Technology, AgJunc …
The global precision farming/agriculture market was valued at 3,833 million in 2017 and is anticipated to reach over USD 13,016 million by 2026 with grow at a CAGR of more than 14.7% during the forecast period According to a new study published by Polaris Market Research. In 2017, the yield monitoring application dominated the global market, in terms of revenue. North America is expected to be the leading contributor to
What are the different trends in Electric Vehicles (EV) Market to boost its grow …
Polaris Market Research has new report published the addition of the “The global Electric Vehicles Market Worth $912 Billion By 2026 | CAGR: 38.4%”, the report classifies the global Electric Vehicles market in a precise manner to offer unearth valuable, accurate and reliable data insights that help organizations to meet their business objectives and enable growth Get PDF Sample of “Electric Vehicles Market”: https://www.polarismarketresearch.com/industry-analysis/electric-vehicles-ev-market/request-for-sample The global electric vehicles market is anticipated to
What are the different trends in Third Party Logistics Market to boost its growt …
Polaris Market Research has new report published the addition of the “The global third-party logistics market is anticipated to reach USD 1,337.91 billion by 2026”, the report classifies the global third-party logistics market in a precise manner to offer unearth valuable, accurate and reliable data insights that help organizations to meet their business objectives and enable growth according to a new report The report “Third Party Logistics (3PL) Market Share, Size,

All 5 Releases


More Releases for Asia

RAMPF Korea – Producing in Asia for Asia
Joint Venture for the Asian markets – The international RAMPF Group has realigned the cooperation with its long-standing partner Orient Dosiertechnik from Korea with the founding of RAMPF Korea Co., Ltd. The new company based in Hwaseong City is developing and producing mixing and dispensing systems specifically for the Asian markets. Within the framework of the new joint venture based in Hwaseong City, mixing and dispensing systems are being developed and
LIXIL Asia Presents Asia Pacific Property Awards
Through its power brands GROHE and American Standard, LIXIL Asia signs a three-year deal to become the Headline Sponsor of the Asia Pacific Property Awards from 2019 until 2022. 23rd January 2019: The International Property Awards, first established in 1993, are open to residential and commercial property professionals from around the globe. They celebrate the highest levels of achievement by companies operating within the architecture, interior design, real estate and property
MES: Expansion in Asia
Berlin, November 24, 2014: Model Engineering Solutions (MES), the Berlin-based specialist for model-based software development, has significantly expanded its business in Asia. In recent years, MES has built up a network of local partners in Japan, Korea, China, and India in order to benefit from the growing market and increasing interest in model-based development and ISO 26262 in Asia. Asia: Driving force in the automotive industry The automotive industry continues
Undersea Defence Technology Asia, UDT Asia 2011
Latest Military Diving Technologies featured in UDT Asia Equipping Asia’s navies with the latest diving technology for asymmetric warfare and operations SINGAPORE, 17 October 2011 - Naval diving and underwater special operations is a field that is seeing increased attention and investment amongst navies in Asia. Units such as the Indonesian Navy‟s KOPASKA, the Republic of Singapore Navy‟s Naval Diving Unit (NDU), the Royal Malaysian Navy‟s PASKAL are increasingly utilising specialised equipment for conducting
UDT Asia 2011
Clarion Events hosts the Undersea Defence Technology (UDT) Asia 2011 conference and exhibition to bring senior naval and industry personnel together to cover underwater developments in the region Singapore, May 30 – Clarion Events is hosting UDT Asia on 30 November – 1 December 2011. The event brings together the undersea defence community in Asia, featuring top regional naval speakers, who will be addressing the latest underwater requirements for Asian navies. According
eltherm goes Asia
Finally all preparations are finished and the new subsidiary of eltherm GmbH, eltherm Asia Pacific Pte Ltd has commenced operations in Singapore on 1st April 2010. To celebrate the starting shot, an opening celebration was held in the afternoon of 28th July in the office premises followed by a get together dinner and drinks in the evening at a pub. A total of 62 guests attended the event with the